Protease Inhibitor

Protease Inhibitor designates therapeutic agents that block the catalytic activity of specific protease enzymes, disrupting disease processes that depend on proteolytic function. This drug class has demonstrated remarkable clinical success across multiple therapeutic areas, from HIV/AIDS treatment to cardiovascular disease management.

HIV protease inhibitors revolutionised AIDS treatment by preventing viral maturation, transforming a fatal diagnosis into a manageable chronic condition. Drugs like ritonavir, atazanavir, and darunavir selectively inhibit HIV protease without affecting human enzymes. Hepatitis C protease inhibitors targeting the NS3/4A protease have achieved sustained virologic responses exceeding 95%, effectively curing a disease previously requiring lengthy interferon-based regimens. Cardiovascular applications include ACE inhibitors blocking angiotensin-converting enzyme, widely prescribed for hypertension and heart failure. The biopharmaceutical industry continues expanding protease inhibitor applications into oncology, neurodegenerative diseases, and inflammatory conditions, employing structure-based design leveraging crystallographic knowledge of protease active sites. As understanding of protease biology deepens, pharmaceutical companies identify novel protease targets and develop next-generation inhibitors with enhanced selectivity profiles.